The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Analyses were conducted separately for patients with and without type 2 diabetes. The study found that most adults with overweight or obesity discontinued GLP-1 RA therapy within a year, with ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...